News & Updates

Show Multimedia Only
Donanemab puts brakes on Alzheimer’s disease progression

Donanemab puts brakes on Alzheimer’s disease progression

26 Jul 2023

In the treatment of individuals with early symptomatic Alzheimer's disease and amyloid and tau pathology, the immunoglobulin G1 monoclonal antibody donanemab helps slow clinical progression, according to the results of the phase III TRAILBLAZER-ALZ 2 study.

26 Jul 2023
Theophylline shows promise in SCI-induced bradycardia

Theophylline shows promise in SCI-induced bradycardia

18 Jul 2023

Use of theophylline as an adjunctive therapy appears to lead to favourable outcomes among patients with bradycardia due to acute spinal cord injury (SCI) with an acceptable response to this agent, suggest the results of a study.

18 Jul 2023